[go: up one dir, main page]

MX2018002338A - Sondas para formar imagenes de proteina de huntingtina. - Google Patents

Sondas para formar imagenes de proteina de huntingtina.

Info

Publication number
MX2018002338A
MX2018002338A MX2018002338A MX2018002338A MX2018002338A MX 2018002338 A MX2018002338 A MX 2018002338A MX 2018002338 A MX2018002338 A MX 2018002338A MX 2018002338 A MX2018002338 A MX 2018002338A MX 2018002338 A MX2018002338 A MX 2018002338A
Authority
MX
Mexico
Prior art keywords
huntingtina
probes
protein
form images
formula
Prior art date
Application number
MX2018002338A
Other languages
English (en)
Other versions
MX382156B (es
Inventor
Dominguez Celia
Wityak John
Bard Jonathan
Edward Prime Michael
John Brown Christopher
Martin Krulle Thomas
CLARK-FREW Daniel
Higgins Duane
Robert MILLS Matthew
Waldron Marston Richard
HAYES Sarah
Coe Samuel
David Johnson Peter
Louise Jones GREEN Samantha
Original Assignee
Chdi Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chdi Foundation Inc filed Critical Chdi Foundation Inc
Publication of MX2018002338A publication Critical patent/MX2018002338A/es
Publication of MX382156B publication Critical patent/MX382156B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nuclear Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan agentes para formar en imagen que comprende un compuesto de la Fórmula I, o una sal farmacéuticamente aceptable del mismo, y métodos para su uso. (ver Fórmula).
MX2018002338A 2015-08-28 2016-08-26 Sondas para formar imagenes de proteina de huntingtina. MX382156B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562211118P 2015-08-28 2015-08-28
PCT/US2016/049112 WO2017040336A1 (en) 2015-08-28 2016-08-26 Probes for imaging huntingtin protein

Publications (2)

Publication Number Publication Date
MX2018002338A true MX2018002338A (es) 2018-07-06
MX382156B MX382156B (es) 2025-03-13

Family

ID=58103449

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002338A MX382156B (es) 2015-08-28 2016-08-26 Sondas para formar imagenes de proteina de huntingtina.

Country Status (18)

Country Link
US (3) US10137211B2 (es)
EP (1) EP3340796B1 (es)
JP (1) JP6944929B2 (es)
CN (1) CN108135172B (es)
AU (1) AU2016315648B2 (es)
BR (1) BR112018003331B1 (es)
CA (1) CA2995847C (es)
DK (1) DK3340796T3 (es)
ES (1) ES2885053T3 (es)
HR (1) HRP20211156T1 (es)
HU (1) HUE056509T2 (es)
IL (1) IL257537B (es)
MX (1) MX382156B (es)
PL (1) PL3340796T4 (es)
PT (1) PT3340796T (es)
RU (1) RU2721419C2 (es)
SI (1) SI3340796T1 (es)
WO (1) WO2017040336A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2959505A1 (en) 2014-08-29 2016-03-03 Chdi Foundation, Inc. Probes for imaging huntingtin protein
BR112017004140B1 (pt) 2014-08-29 2023-01-10 Chdi Foundation, Inc. Agente de imagemamento, seu uso e compostos
MX383202B (es) 2014-08-29 2025-03-13 Chdi Foundation Inc Sondas para la proyección de imagen de la proteína huntingtina.
CN107108534B (zh) 2014-08-29 2023-05-09 Chdi基金会股份有限公司 用于成像亨廷顿蛋白的探针
AU2016315648B2 (en) 2015-08-28 2021-04-01 Chdi Foundation, Inc. Probes for imaging huntingtin protein
WO2019157272A1 (en) * 2018-02-08 2019-08-15 Phraxis Inc. One piece anastomotic connector
EP3931186A1 (en) 2019-02-25 2022-01-05 CHDI Foundation, Inc. Compounds for targeting mutant huntingtin protein and uses thereof
US11918662B2 (en) 2020-06-11 2024-03-05 Chdi Foundation, Inc. Heterocyclic compounds and imaging agents for imaging huntingtin protein
KR20240024045A (ko) * 2021-04-08 2024-02-23 씨에이치디아이 파운데이션, 인코포레이티드 헌팅틴 단백질 영상화를 위한 아이소인돌리논 화합물 및 영상화제

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69321875T2 (de) * 1992-05-19 1999-06-17 Adir Et Compagnie, Courbevoie Benzimidezolderivate mit antidiabetischer und Anti-Plättchenklumpungswirkung
JP2000351782A (ja) * 1999-04-06 2000-12-19 Yamanouchi Pharmaceut Co Ltd メタボトロピックグルタメート受容体作用薬及び新規チアゾロベンゾイミダゾール誘導体
AU2241400A (en) * 1999-04-06 2000-10-12 Yamanouchi Pharmaceutical Co., Ltd. Novel thiazolobenzoimidazole derivative
UY27003A1 (es) * 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
US20050267182A1 (en) * 2003-11-13 2005-12-01 Ambit Biosciences Corporation Urea derivatives as FLT-3 modulators
TW200736252A (en) * 2006-01-27 2007-10-01 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
FR2919610B1 (fr) * 2007-08-02 2009-10-16 Sanofi Aventis Sa Derives de n-heteroaryl-carboxamides tricycliques,leur preparation et leur application en therapeutique
WO2010011964A2 (en) * 2008-07-24 2010-01-28 Siemens Medical Solutions Usa, Inc. Imaging agents useful for identifying ad pathology
EP2218464A1 (en) * 2009-02-11 2010-08-18 Technische Universität München Compounds for non-invasive measurement of aggregates of amyloid peptides
CA2756137C (en) * 2009-03-23 2015-11-24 Siemens Medical Solutions Usa, Inc. Imaging agents for detecting neurological disorders
BR112015000561A2 (pt) 2012-07-11 2017-06-27 Nimbus Iris Inc inibidores de irak e usos dos mesmos
US9902702B2 (en) * 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
BR112017004140B1 (pt) 2014-08-29 2023-01-10 Chdi Foundation, Inc. Agente de imagemamento, seu uso e compostos
MX383202B (es) 2014-08-29 2025-03-13 Chdi Foundation Inc Sondas para la proyección de imagen de la proteína huntingtina.
CN107108534B (zh) 2014-08-29 2023-05-09 Chdi基金会股份有限公司 用于成像亨廷顿蛋白的探针
CA2959505A1 (en) 2014-08-29 2016-03-03 Chdi Foundation, Inc. Probes for imaging huntingtin protein
AU2016315648B2 (en) 2015-08-28 2021-04-01 Chdi Foundation, Inc. Probes for imaging huntingtin protein

Also Published As

Publication number Publication date
CA2995847A1 (en) 2017-03-09
US10137211B2 (en) 2018-11-27
IL257537A (en) 2018-04-30
US10765764B2 (en) 2020-09-08
BR112018003331A2 (pt) 2018-11-06
IL257537B (en) 2020-08-31
JP2018531897A (ja) 2018-11-01
CN108135172B (zh) 2021-03-30
US20190167821A1 (en) 2019-06-06
JP6944929B2 (ja) 2021-10-06
PL3340796T3 (pl) 2022-02-21
AU2016315648A1 (en) 2018-03-29
BR112018003331B1 (pt) 2022-05-10
US20170056535A1 (en) 2017-03-02
DK3340796T3 (da) 2021-07-26
RU2721419C2 (ru) 2020-05-19
EP3340796A1 (en) 2018-07-04
PT3340796T (pt) 2021-07-28
RU2018110055A (ru) 2019-09-30
EP3340796A4 (en) 2019-05-15
RU2018110055A3 (es) 2019-10-28
CN108135172A (zh) 2018-06-08
AU2016315648B2 (en) 2021-04-01
WO2017040336A1 (en) 2017-03-09
SI3340796T1 (sl) 2022-02-28
HUE056509T2 (hu) 2022-02-28
ES2885053T3 (es) 2021-12-13
PL3340796T4 (pl) 2022-02-21
MX382156B (es) 2025-03-13
EP3340796B1 (en) 2021-04-21
US20210060187A1 (en) 2021-03-04
CA2995847C (en) 2024-05-28
HRP20211156T1 (hr) 2021-12-24
US11344637B2 (en) 2022-05-31

Similar Documents

Publication Publication Date Title
MX2018002338A (es) Sondas para formar imagenes de proteina de huntingtina.
MX2017002703A (es) Sondas para la proyección de imagen de la proteína huntingtina.
IL282304A (en) Topical pharmaceutical compositions
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
CY1123633T1 (el) Ετεροκυκλικες ενωσεις και οι χρησεις αυτων
CL2018003291A1 (es) Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).
GT201600085A (es) Composiciones y métodos para modular los receptores x farnesoides
CO2017012893A2 (es) Composiciones farmacéuticas que comprenden péptidos neo-antígenos o una sal de los mismos y métodos para preparar las mismas
CL2017000654A1 (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CL2017003240A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
MX2016016886A (es) Anticuerpos anti-axl.
MX2017002702A (es) Sondas para la proyección de imagen de la proteína huntingtina.
EA201790408A1 (ru) Зонды для визуализации белка хантингтина
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
EA029499B9 (ru) Ингибиторы rorc2 и способы их применения
CL2017000640A1 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
CR20160061A (es) Formulación estable líquida de etelcalcetide (amg 461)
SV2019005838A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
BR112017002675A2 (pt) métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila
ES2611776T3 (es) Uso de sales de tungsteno (VI) para el tratamiento de la esterilidad femenina en mamíferos no diabéticos
AR100289A1 (es) Formas de un inhibidor de pi3k
MX2016009471A (es) Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso.